HYPERFINE Stock Price, News & Analysis

Hyperfine (NASDAQ: HYPR) announced FDA clearance on December 15, 2025 for the first Optive AI™ software update: a multi-direction diffusion-weighted imaging (DWI) sequence for the Swoop® portable MRI system. The sequence acquires and averages signals from multiple directions to produce cleaner, more consistent diffusion images, improving sensitivity for smaller strokes and specificity for true infarcts. The existing single-direction DWI remains available for faster imaging in ultra-urgent stroke protocols. The update is available for all Swoop system models and is positioned to expand the system's clinical role in acute neurological and hospital care settings.

Hyperfine (Nasdaq: HYPR) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:10 AM ET. The company, maker of the FDA-cleared AI-powered portable brain MRI Swoop®, will provide a live audio webcast with an archived recording available on its investor website. Management will hold in-person one-on-one meetings; investors should contact their Piper Sandler representative or the company’s investor contact to schedule.

Hyperfine (Nasdaq: HYPR) received a $3.7 million Gates Foundation grant to expand AI-powered portable neonatal MRI work through 2028. Funding will accelerate AI pipelines and technical innovation for the Swoop® portable MRI to evaluate infant neurodevelopment in resource-constrained settings as part of the UNITY project led by King’s College London.

The UNITY consortium spans >40 centers across low-, middle-, and high-income countries and has performed >10,000 examinations, including scans of >6,000 babies across five continents; the grant targets improved image clarity and diagnostic reliability for neonatal scans.

Hyperfine (Nasdaq: HYPR) reported third quarter 2025 results and a business update on November 13, 2025. Q3 revenue was $3.4M, up 27% sequentially, with 8 commercial Swoop systems sold (5 next generation). Gross margin was a record 53.8% ($1.8M), up 450 basis points QoQ. Net loss was $11.0M ($0.14/share), compared with $9.2M in Q2; the quarter included a $2.3M fair-value change on warrant liabilities.

Company launched next generation Swoop and Optive AI, expanded into neurology offices, obtained CE Mark and UKCA for Optive AI, raised $20.1M in October, and guided Q4 2025 revenue to $5–$6M and FY2025 revenue to $13–$14M.

Hyperfine (Nasdaq: HYPR) will report full third quarter 2025 financial results on Thursday, November 13, 2025. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live audio webcast and archived recording available on the company Investors page.

Participants are encouraged to register at least 15 minutes before the call. The company notes its FDA-cleared AI-powered portable brain MRI, the Swoop system, and directs users to HyperfineMRI.com for product information.

Hyperfine (Nasdaq: HYPR) announced that the PRISM PMR study has enrolled its first patients to evaluate the Swoop® portable MRI system in the neurosurgical operating room.

PRISM PMR (PRe- and post-operatIve Study of iMaging with Portable MR) will collect real-world data over three months at Atlas Surgery Center in Buffalo, NY, led by principal investigator Dr. Elad Levy. The study will assess pre- and post-procedure imaging across diverse neurosurgical procedures, detection of post-operative complications (stroke, bleeding), and workflow integration to support faster discharge and recovery.

Hyperfine (Nasdaq: HYPR) priced a registered underwritten public offering of 14,000,000 Class A shares at $1.25 per share, with gross proceeds to the company of approximately $17.5 million before fees. The underwriter has a 30-day option to purchase up to 2,100,000 additional shares (15% of the offering) at the same public price less underwriting discounts.

The offering is expected to close on or about October 17, 2025, subject to customary closing conditions. Lake Street Capital Markets is sole book-runner. Proceeds are intended for working capital and general corporate purposes, including commercial, manufacturing, and R&D. The securities are offered under an effective Form S-3 shelf registration.

Hyperfine (Nasdaq: HYPR) announced on October 15, 2025 that it has commenced an underwritten public offering of its Class A common stock or, for certain investors, pre-funded warrants to purchase Class A common stock. The company said all securities will be sold by Hyperfine and that underwriters will have a 30-day option to buy up to 15% of the total securities on the same terms. The offering is subject to market and other conditions and may not be completed.

Lake Street Capital Markets is sole book-runner. The securities are offered from an effective Form S-3 shelf registration (filed Nov 9, 2023; declared effective Nov 22, 2023). Final terms will be disclosed in a prospectus supplement filed with the SEC.

Hyperfine (Nasdaq: HYPR) reported preliminary, unaudited Q3 2025 results and business progress following the launch of the next generation Swoop system and Optive AI software. Preliminary Q3 revenue is expected to be ~$3.4M (sequential +27%); preliminary effective average device selling price is ~$360,000 (sequential +36%).

In Q3, 5 of 8 commercial Swoop systems sold (63%) were next generation units. Preliminary cash burn was ~$5.9M (sequential -27%), with preliminary cash and cash equivalents of ~$21.6M as of September 30, 2025. The company began office-setting launches and Optive AI rollout to installed base in US, Canada, Australia, and New Zealand.